Melanoma Checkpoint Therapy More Potent in Combination with Nanovaccine

GEN | August 06, 2019

Dissonant signaling, which can deafen the immune system to cancer, can be replaced by something more harmonious and therapeutic if immunotherapies silence a note, sound another, or play an especially resonant chord. This last approach was taken by researchers based at Tel Aviv University (TAU) when they decided to score a requiem for melanoma, the most aggressive type of skin cancer. Performing in vitro and animal studies, the TAU scientists combined several forms of immunotherapy, reaching a most effective crescendo when they added a nanovaccine—a particle made of biodegradable polymer, sized at 160–190 nanometers, and packed with tumor-associated antigens. Actually, two nanovaccines were evaluated. One was studded with mannose receptors and capable of ligand-mediated (active) targeting of dendritic cells. The other was mannose free and capable only of phagocytosis-dependent (passive) targeting. When the mannosylated nanovaccines were combined with an anti-PD-1 antibody (αPD-1) for immunosuppression blockade and an anti-OX40 antibody (αOX40) for effector T-cell stimulation, expansion, and survival, robust and widespread complementary outcomes against melanoma were achieved. Details of this work appeared August 5 in the journal Nature Nanotechnology, in an article titled, “Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators.”

Spotlight

University professors and public sector scientists are regarded as highly credible sources of information on biotechnology. Hence, their role in science communication, particularly on biotechnology is critical. A survey was conducted to investigate how Filipino academics and scientists involved in crop biotechnology view science communication and their role in public awareness and understanding.

Spotlight

University professors and public sector scientists are regarded as highly credible sources of information on biotechnology. Hence, their role in science communication, particularly on biotechnology is critical. A survey was conducted to investigate how Filipino academics and scientists involved in crop biotechnology view science communication and their role in public awareness and understanding.

Related News

INDUSTRIAL IMPACT

Verantos Named "BioInformatics Company of the Year" by BioTech Breakthrough

BioTech Breakthrough, Verantos | October 28, 2021

Verantos, the market leader in high-validity real-world evidence (RWE) generation, today announced it has been named "BioInformatics Company of the Year" in the inaugural BioTech Breakthrough Awards program conducted by BioTech Breakthrough. This independent market intelligence organization evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. The Verantos real-world evidence (RWE) platform leverages data science, artificial intelligence, and advanced data sources to generate evidence that enables precision medicine. It also provides a more inclusive approach to a learning healthcare system, in which underrepresented populations are better represented than in other evidence generation approaches. The platform is able to de-identify, enrich, and integrate data from electronic health records, medical claims, and registries to produce exacting and exceptionally valid RWE. Bryan Vaughn, Managing Director of BioTech Breakthrough Awards said, "Verantos continues to develop high-validity RWE in collaboration with pharmaceutical, regulatory and scientific institutions, enabling personalized medicine, and improved, more efficient care. Congratulations on being our choice for 'BioInformatics Company of the Year." Verantos has generated advanced RWE for top-tier biotechnology and pharmaceutical firms in addition to leading academic medical centers and health systems. It has also developed advanced science funded by the Food and Drug Administration, the National Institutes of Health, and the National Science Foundation. Additionally, Verantos CEO Dan Riskin testified before Congress on the 21st Century Cures Initiative and has helped shape policy in the use of advanced clinical data and technologies. These partnerships and initiatives have allowed Verantos to trailblaze in their industry and benefit patients living with common conditions across the globe. "We are thrilled to receive this award from BioTech Breakthrough. It supports our mission to advance real-world evidence to improve the standard of care, and furthers our vision to pioneer personalized medicine by setting the quality standard for real-world evidence. said Dan Riskin, CEO of Verantos. The annual BioTech Breakthrough Awards program conducts the industry's most comprehensive analysis and evaluation of the top technology companies, solutions and products in the life sciences and biotechnology industry today. This year's program attracted more than 1,200 nominations from over 12 different countries throughout the world. About Verantos Verantos is the market leader in high-accuracy, real-world evidence generation. The Verantos RWE platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for regulatory and reimbursement use. The Verantos RWE platform leverages data science and artificial intelligence along with advanced data sources such as electronic health records to generate RWE capable of supporting clinical assertions. About BioTech Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more.

Read More

MEDTECH

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effective when we enter the clinical evaluation stage,” said Jack O’Meara, CEO at Ochre Bio. “As we are progressing our preclinical evaluation, we are proud to support the great work of the British Liver Trust. We highly appreciate their effort in supporting patients, caregivers, and healthcare professionals on all aspects of liver health including prevention and early detection, and we look forward to a close partnership as we execute on our unified goal.” The British Liver Trust is the UK's leading liver health charity, recognised by Her Majesty's Revenue and Customs and the Charity Commissions in England, Wales and Scotland, is working to improve liver health and supporting patients affected by liver disease or cancer. Reaching millions of people each year, the British Liver Trust raises awareness for the risk factors of liver disease, provides advice to help people improving their liver health and submits the most updated information to patients. “In the UK, one out of six patients dies while waiting for a liver transplant. Ochre Bio’s research has the potential to improve these numbers and with that the chances of successful treatment for liver disease patients. We are really excited that Ochre Bio is supporting the aims of the British Liver Trust and we delighted to have this partnership with important shared goals,” Pamela Healy OBE, Chief Executive of the British Liver Trust About Ochre Bio Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. We uncover new biological pathways by using advances in 'deep phenotyping', and then study our medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines we bring to the clinic are highly likely to successfully improve patient lives. Situated within the heart of Oxford’s biotech innovation hub, Ochre is built on over 15 years experience in liver genomics and bringing advanced therapies to market.

Read More

Xylyx Bio Releases Normal and Fibrotic NativeCoat™ ECM Substrates Increase Predictiveness of High Throughput Compound Screening

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to the lack of translatability of preclinical data to humans. Existing models do not replicate the complexity of human disease, impeding the translation of research to patients and contributing to numerous and expensive drug failures. To address this need, NativeCoat™ substrates harness the power of human disease-specific extracellular matrix (ECM) to combine the advantages of scalability and throughput with the ability to incorporate higher-level biology and generate translatable data.

Read More